Archive for November, 2012

PFSweb, Inc. (PFSW) Reports Record Customer Traffic Volumes for Clients at the Outset of the 2012 Holiday Shopping Season

Friday, November 30th, 2012

International provider of end-to-end e-commerce solutions PFSweb has announced record consumer traffic and order volumes for the beginning of the 2012 holiday shopping season for its North American End2End consumer packaged goods (CPG), luxury, cosmetic, and apparel clients’ e-commerce direct-to-consumer (E2E DTC) brand sites.

During the course of the Thanksgiving period (Nov. 22 to Nov. 26, including Black Friday and Cyber Monday), PFSweb’s CPG, luxury, cosmetic, and apparel E2E DTC clients’ brand sites in North America received around 364,000 customer orders, with an average order value of more than $102. The company’s client Web sites additionally experienced robust customer traffic, logging approximately 8 million total sessions, which included around 3.7 million new visitors.

On the whole, PFSweb’s North American CPG, luxury, cosmetic, and apparel E2E DTC clients’ brand sites also reported strong same-store-order volumes as compared with the similar period for 2011. This included a 69 percent increase in total customer orders and a 45 percent increase in new visitors. The same-store sales data encompasses data from the CPG, luxury, cosmetic, and apparel E2E DTC clients’ brand e-commerce sites that were operating during the 2011 and 2012 holiday shopping seasons and were supported by PFSweb during both time periods.

As PFSweb anticipated in its operational plans and financial forecasts, the 2012 holiday online retail season in the United States has shown significant improvement over 2011. Infrastructure and technology investments made by PFSweb this year have produced measurable operation benefits for the company and its clients as PFSweb scales its solution to help clients capitalize on the season’s sales opportunities.

PFSweb is engaged in enabling the e-commerce initiatives of iconic brands. The company’s End2End e-commerce solution features interactive marketing services, strong e-commerce technology, global fulfillment and logistics, high-touch customer care, financial services, and order management. The company’s e-commerce solutions offer international reach and expertise in both direct-to-consumer and business-to-business initiatives, supporting organizations across various industries. Headquartered in Allen, Texas, PFSweb has additional locations in Tennessee, Mississippi, Canada, Belgium, and the Philippines.

For more information, visit www.PFSweb.com

Let us hear your thoughts below:

ModusLink Global Solutions, Inc. (MLNK) Wins 4th Green Supply Chain Award

Friday, November 30th, 2012

ModusLink Global Solutions recently announced that the company has won recognition, for the fourth consecutive year, at Supply & Demand Chain Executive Magazine’s 2012 Green Supply Chain Awards. An award was won for helping a partner achieve a reduction in packaging design.

ModusLink is focused on providing supply chain logistics services to help improve their clients’ revenue, cost, sustainability, and customer experience objectives. ModusLink has clients in such diverse industries as consumer electronics, communications, computing, medical devices, software, luxury goods, and retail, while supporting more than $80 billion of its clients’ revenue. The company manages approximately 470 million product shipments through more than 30 sites in 15 countries.

The Supply & Demand Chain Executive Magazine award was won by helping a ModusLink client reduce the packaging material of its line of flash memory products, including USB and USB Mini devices, SD cards, and Micro SD cards. The goal of the project was to reduce greenhouse gas emissions as well as the volume of packaging material and shipping costs. The new packaging design resulted in a 50 – 80% reduction of paper use, 50% reduction in plastics, 157% average increase in pallet density for shipping, and a 45% reduction in shipping costs.

“A key challenge that many companies encounter in their sustainability efforts is the difficulty that comes with changing business as usual,” said Lorcan Sheehan, senior vice president of marketing, ModusLink. “An example in this case was the entrenched belief that each product should be accompanied by a comprehensive product manual. Our packaging engineers worked to find an innovative solution that allowed for printing instructions directly onto the blister pack. We helped the client meet its aggressive sustainability goals by eliminating the separate manual, but also took into account the company’s need to ensure all necessary product information was readily available to consumers.”

For more information, visit www.moduslink.com

Let us hear your thoughts below:

Flexpoint Sensor Systems, Inc. (FLXT) Releases Series of Promotional Videos

Friday, November 30th, 2012

Flexpoint Sensor Systems recently announced that a series of professional promotional videos is now available on the company’s YouTube page. The videos promote the company’s Bend Sensor® technology’s features, advantages, and market potential. Interested parties can access the videos at http://www.youtube.com/user/FlexpointSensor. Flexpoint anticipates that the videos will prove useful as the company expands and gains momentum.

As of Thursday, the company’s YouTube account boasts seven new videos that show the basic manufacturing process and feature demonstrations of how the technology is used in various applications. The videos also highlight a broad range of sensor variations in order to give viewers a sense of the versatility of the technology.

The videos are part of the company’s effort to overhaul its website and represent the latest efforts in Flexpoint’s ongoing marketing push. The YouTube account also contains links to videos uploaded by different users of Bend Sensor® technology. Most of these other videos were shot on low-resolution cameras purely for demonstration purposes and are not considered part of Flexpoint’s formal marketing campaign.

Flexpoint CEO, Clark Mower remarked, “The Bend Sensor® can be challenging to fully describe and its unique features and advantages often only become apparent when we are able to demonstrate the technology in person. With these videos, we aimed to recreate the experience of sitting down with us here at our offices for a full hands-on demonstration. We think these videos do a nice job of providing the basics of what the technology can do and clarify how it is being utilized in various products. Whenever individuals get a vivid sense of what the Bend Sensor® is capable of, they invariably begin to generate new ideas for how it can be used. These videos should help get those creative wheels turning and we are excited to see the responses we get as more and more people see them.”

For more information, visit www.flexpoint.com

Let us hear your thoughts below:

Loans4Less.com, Inc. (LFLS) Positioned to Benefit from Growing Housing Demand

Friday, November 30th, 2012

What a difference a year can make. Toward the end of 2011, the real estate market, and all of the industries that depended upon it, were struggling as perhaps never before in history, and it seemed like the housing slump would continue forever. Housing prices had dropped again in 2011, though not by much, and nothing compared to the double digit losses experienced earlier in the recession.

By some measures, housing prices finally hit a low in February of 2012, and then began to show some life, initiating quarterly rises that continue today. It was the end of a 5-year slide that began back in early 2007. Most recently, the Federal Housing Finance Agency’s seasonally adjusted purchase-only house price index rose by 1.1 percent from the 2nd quarter to the 3rd quarter of 2012. Over the latest four quarters, the index is up 3.3 percent.

The earlier flood in housing inventory is now just a memory, with supply beginning to tread historic lows, down most recently by 17% year-over-year in October 2012. Delinquency rates have also dropped year-over-year and existing home sales are rising. Housing production is also up, though fed more by multi-unit properties, with builder confidence hitting a post crisis high.

This is all exceptional news for real estate based companies such as growing online mortgage loan broker Loans4Less.com. Although the real estate industry is a lot thinner than it used to be, those companies that are around now face a wealth of pent up demand, moderated only by the stricter mortgage policies now in place. And these policies are not as much of a challenge to Loans4Less, which focuses on “A” paper loans. Moreover, the fire is being further stoked by historically low mortgage interest rates.

For more information, visit www.Loans4Less.com

Let us hear your thoughts below:

Synergy Resources Corp. (SYRG) Expands Line of Credit from Colorado Banks to $47 Million

Friday, November 30th, 2012

Synergy Resources is a domestic oil and natural gas exploration and production company. Its focus currently is on the Denver-Julesberg Basin, which encompasses areas in the states of Colorado, Wyoming, Nebraska, and Kansas. The Watterberg Field in the Basin ranks as one of the most productive fields in the United States.

The company reported today that it has amended its revolving line of credit agreement with an expanded syndicate group comprised of Community Banks of Colorado, Colorado Business Bank, and Amegy Bank National. Synergy’s long-term debt totaled roughly $3 million at fiscal year-end on August 31, 2012.

The amended terms of the agreement includes an increase to $47 million in the borrowing base versus $30 million under the prior agreement. The maximum amount of borrowing power available to Synergy under the new agreement is $150 million. This amount is subject to certain borrowing base collateral requirements, which will be reviewed by the syndicate banks every six months. The maximum interest rate on the line of credit is LIBOR plus 3.25%. The term of the line of credit has been extended to mature in November 2016.

Synergy Resources anticipates using this expanded credit line to complete the acquisition of Orr Energy, which was announced on October 23, 2012. This transaction is expected to close in early December. The company will also tap the credit line to fund part of its fiscal 2013 capital expenditure budget.

For further information about Synergy Resources and its exploration projects, visit www.syrginfo.com

Let us hear your thoughts below:

Viscount Systems, Inc. (VSYS) is “One to Watch”

Friday, November 30th, 2012

Viscount Systems designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.

Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.

Five hundred dealers help distribute Viscount’s existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.

Viscount’s management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company.

For more information, visit www.viscount.com

Let us hear your thoughts below:

Command Center, Inc. (CCNI) Notches Significant Improvement in November, YTD Sales

Friday, November 30th, 2012

Command Center, a nationwide provider of on-demand and temporary staffing solutions, today reported significant increases in its November and year-to-date 2012 revenues.

Revenue for the four-week reporting period of November 2012 increased 38 percent to $8.34, as compared to revenue of $6.05 million for the comparable period of 2011.

Year-to-date, Command Center has recorded revenue of $89.53 million, an increase of 19 percent, as compared to $75.06 million in revenues reported for the comparable year-ago period.

Command Center attributes its sales growth to the opening of seven stores in the course of a year, which now stand at 59 company-owned stores vs. 52 stores one year ago.

Revenues were also strengthened by the company’s disaster relief activities in New York and New Jersey in the wake of Hurricane Sandy. Command Center said it continues to be actively involved in assisting the areas’ recovery efforts by dispatching between 200-500 workers each day, for six or seven days every week.

During the month of November, Command Center also opened a new branch office, the second in the Phoenix area, which allows the company to focus primarily on placing personnel in the construction trades.

“Expansion over the past year into new areas like disaster relief has provided the catalyst for greater stability in our revenue growth, particularly coming into the current quarter. And the opening of the new Phoenix construction trades office points to our continued focus on identifying and taking advantage of niche market opportunities,” Command Center’s chairman and CEO, Glenn Welstad stated in the press release. “We look forward to strong fourth quarter results and a record year in 2013.”

For more information visit www.commandonline.com

Let us hear your thoughts below:

National Graphite Corp. (NGRC) Chedic Property in Nevada Shows up to 40% Grade on Some 1M Tons

Friday, November 30th, 2012

National Graphite is positioning itself quite well for huge upcoming moves in the underlying supply/consumption dynamics of the graphite industry, with substantial acreage up in the rich Canadian flake in Quebec, as well as their Chedic Graphite Property in Nevada. The company reported some strong assay results today from sampling taken at the main Chedic production pit, showing a 25-40% grade with the potential to bring in over 1M tons of high-quality graphite.

Independent Geologist contracted by NGRC, John Rud, cited the recent geophysical survey data which showed a target well over 1,500 feet deep ranging from 50 to 150 feet wide, not including the new anomaly, as a strong lead-in indicator of the mineral potential here. Carefully targeted drilling under the soon to be permitted program will be ferreting out the true potential of this exciting site, consisting of 20 mineral lode claims just four miles outside Carson City. The continuous enriched structure was originally started back in the 1900′s with very minimal production ever done and now looks to be richer than ever imagined.

The forthcoming drilling will examine several low resistivity anomalies to the east which represent a clear extension capability for the main production area. Rud noted that the localized geology at Chedic, taken in concert with today’s findings and the existing analytical work, makes the entire project “extremely compelling.” The company obviously has a nice, large, second zone opening up here.

The first anomaly to the east (820 feet from the pit) runs alongside an exploration trench that exposed graphite mineralization and is roughly 1,640 feet or more deep, in excess of 160 feet wide (with a second anomaly detected just north indicating the true width of mineralization may be three times higher at around 490 plus feet). A second drill target just under 1k feet further over plunges to a depth of 1.2k feet at over 100-foot widths. National Graphite’s drilling program will fully probe the relevant anomalies, with a keen eye towards determining the overall grade in both.

Demand for graphite is set to jump 10-12% per year in battery manufacturing alone (Natural & Synthetic Graphite: Global industry markets & outlook, 8th edition 2012). You take into account delimiting of exports by top producer China and a massive future in nanotech where the demand for graphene will be through the roof and you have a perfect logistical storm that benefits small, domestic graphite producers like NGRC.

The company also maintains the Black Butte Project (silver-gold) outside Hawthorne, NV, which has some solid secondary target/indicator metals and clear indications that the relatively limited extant workings are the top of a larger epithermal quartz vein system.

For more information on National Graphite, visit www.NationalGraphiteCorp.com

Let us hear your thoughts below:

Synacor, Inc. (SYNC) Appoints Cloud Software Expert Steve Davi as Senior Vice President, Software Engineering

Thursday, November 29th, 2012

Synacor, leading provider of next-gen startpages, TV Everywhere solutions, and cloud-based services across multiple devices for cable, satellite, telecom, and consumer electronics companies, today announced that Steve Davi has been appointed as senior vice president, software engineering. Prior to Synacor, Davi worked for SeaChange International, Banyan Systems, and Data General, gaining proven experience in cloud software engineering, digital media, HTML5, over-the-top, mobile, and advertising monetization models.

Scott Bailey, Synacor COO, said, “We are excited to have Steve Davi, an accomplished software engineer and respected team leader, join Synacor as we continue expanding the multiscreen environment for pay-TV providers, increasing subscriber engagement and presenting new revenue opportunities and growth internationally. During this unprecedented time of transformation in digital entertainment, Steve’s 25 years of software experience and insight will ensure Synacor continues innovating and launching new products so our customers can provide subscribers their favorite shows, music, games, news, and cloud services, all in one place, any time, anywhere, on the device of their choosing.”

Previously, Davi worked at SeaChange International for 15 years, most recently holding the position of chief technology officer where he was responsible for overall software technology architecture and company strategy related to product design, system planning, and industry standards. During his time at SeaChange, Davi led the development of several video-on-demand, content management, search, and social media products, including its AssetFlow and Adrenalin platforms. Davi also managed the company’s first VOD product, first Recording System deployment, and first ads in VOD deployment, as well as the company’s multiscreen video software team. Prior to SeaChange International, Davi worked in software engineering leadership and contributor roles at Banyan Systems and Data General. Davi obtained his BS in Computer Science from Worcester Polytechnic Institute and holds an MS in Computer Science from Northeastern University.

“Synacor has quickly emerged as the leader in innovating next-gen startpages, TV Everywhere, cloud services and identity management, and I’m thrilled to have the opportunity to work with Synacor’s world-class team of engineers, developers, and product managers during this breakthrough era in multi-device engagement,” stated Davi. “Giving pay-TV subscribers what they want results in more monetization opportunities for both Synacor and our customers. Look for our software strategy to allow us to accelerate and continue to lead in identity management, cloud services, TV Everywhere, and digital advertising.”

For more information on Synacor, visit www.synacor.com

Let us hear your thoughts below:

International Stem Cell Corp. (ISCO) Advances Groundbreaking Stem Cell Therapy with Distinct Advantages and Capabilities

Thursday, November 29th, 2012

International Stem Cell Corp., a biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), has achieved a critical milestone towards the clinical development of its non-embryonic stem cell therapy.

Through much dedication and hard work, the company’s research and development team has created the world’s first human clinical-grade stem cell lines that can be immune-match to millions of individuals. ISCO’s existing research-grade parthenogenetic stem cell lines, one of which may be an immune-match to approximately 70 million people, are being used in pre-clinical development. ISCO is now in a position to conduct clinical trials in the United States.

“We’ve been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and I’m excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. I’m optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide,” stated Dr. Semechkin, CEO and Co-Chairman of the Board.

Created using ISCO’s proprietary technology, the new stem cell lines represent the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is necessary to conduct clinical development programs.

Independent third-party testing has confirmed the new lines to be “homozygous” in the HLA coding regions. This means that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection; a distinct clinical advantage over embryonic stem cells. The company anticipates the new lines to immune-match millions of individuals. They will be added to ISCO’s existing bank and provide a platform from which to develop cells and tissue for clinical use.

“The importance of this breakthrough cannot be overstated,” emphasized Dr. Craw, Executive Vice President of ISCO. “Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company.”

To learn more about ISCO and its superior stem cell technology, visit www.InternationalStemCell.com

Let us hear your thoughts below:

Envivio, Inc. (ENVI) Solution Deployed by LG U+ for First Korean Google TV Service

Thursday, November 29th, 2012

Envivio, a prominent supplier of live and on-demand multi-screen IP video processing and delivery solutions, announced that Envivio encoding solutions have been deployed by LG U+ to power its new LG u+tv G multi-screen service. This service is the first offering in South Korea boasting support for Google TV. LG u+tv G uses an Internet-connected set-top box to give subscribers access to live channels and on-demand TV integrated with apps, including Search, YouTube, Google Play, and Chrome.

LG U+ is currently using Envivio encoders to run its TV Everywhere service, providing over 126 channels of video to TVs, PCs, tablets, and smartphones. LG U+ is a subsidiary of LG Group and a major telecommunications service provider in Korea.

“We are excited to be able to offer the LG u+tv G service to our subscribers as another way to experience television in an interactive fashion,” said Hyunil Moon, general manager of the IPTV business team at LG U+. “The Envivio encoders were selected because they provided the best video quality at any given bitrate, on any device. This decision was reinforced by the fact that our previous implementation of multi-screen with the Envivio systems has proven to be an extremely reliable, robust architecture.”

“LG U+ is an innovative operator, and the introduction of this new Google TV service takes their video service to the next level,” said Julien Signès, Envivio’s president and CEO. “At Envivio, we are committed to providing solutions that offer the flexibility and scalability our customers need, with the feature set to support traditional TV and advanced applications on any viewing device.”

Envivio Muse™ Live and On-Demand software encoders/transcoders provide high quality video to any device on any network in all formats. Envivio Muse can be upgraded with minimal effort due to its converged architecture and feature-rich, software based design. The system runs on the Envivio 4Caster™ Intel-based appliances or HP blade servers.

For further information, visit www.envivio.com

Let us hear your thoughts below:

Growing Coal with VIASPACE, Inc. (VSPC)

Thursday, November 29th, 2012

Coal and other fossil fuels have been the energy foundation of the industrialized world, providing the power to essentially move the earth, allowing us to reorganize virtually everything to suit our own perceived purposes. But all of this energy comes from someplace, and that someplace is the sun, or, more specifically, the sun from millions of years ago. In the case of coal, it comes from plants that captured solar energy, were ultimately buried, and are now being dug up in the form of coal to release that stored up energy. (It’s much the same with oil, except that oil comes primarily from the remains of ancient animals that ate some of those plants.) These fossil fuels are efficient and convenient stores of energy, ready to burn whenever and wherever needed, including in power plants where coal is used to generate nearly half of all the electricity produced.

But more than energy is released when coal or other fossil fuels are burned, and therein lies the problem. When those plants were living things, they also captured carbon from the air, using the sun’s energy to combine carbon with hydrogen to form the compounds that eventually became coal. When coal is burned, that ancient carbon is released back into the atmosphere in the form of carbon dioxide (CO2), the greenhouse gas that is causing so much consternation today. Going through the massive process of shutting down all of those coal-fired power plants, and bringing online wind or solar or other renewable sources is daunting and expensive. Power plants based on combustion are a tried and true technology all over the world, not requiring sunny or windy days to operate efficiently, but coal is also the single biggest air polluter.

Viaspace, a renewable energy company, has found a way for the world to continue enjoying the proven convenience and dependability of combustion-based electricity with none of the downside. Viaspace is the proprietary holder of Giant King Grass, one of the highest yielding biomass crops in the world. Rather than using unpredictable and difficult to transport waste materials for renewable power sources, the idea is to use Giant King Grass as a dedicated and controllable energy source. In various parts of the world, it can be grown right alongside the power plants it is designed to feed, or it can be pelletized for easy transport anywhere it is needed. But, most importantly, Giant King Grass is carbon neutral, meaning that the CO2 emitted when burned is offset by the absorption of CO2 during its growth. In effect, Viaspace is able to grow its own coal.

For more information, visit www.viaspace.com

Let us hear your thoughts below:

Bluefly, Inc. (BFLY) Names New Chief Financial Officer

Thursday, November 29th, 2012

Bluefly is a leading online retailer of fashion brands, fashion trends, and superior value. In 2011, the company added to its portfolio by launching Belle & Clive, a members-only shopping destination that presents selections of top brands via limited-time sales.

The company announced today that James Gallagher has joined Bluefly as its Chief Financial Officer. He comes to Bluefly with over 33 years of extensive financial, strategic, and operations experience with growth-oriented international, entrepreneurial, and corporate entities across a broad range of industries. These industries included internet-focused marketing, e-commerce, entertainment, and technology.

Most recently, Mr. Gallagher was CFO at Vertro, an internet search engine, marketing, and technology company that manages a network of websites. It also builds and markets browser-based consumer applications. Prior to his stint at Vertro, Mr. Gallagher owned and operated Gallagher Enterprises, a strategic financial and management consulting firm he founded in 2001. It provided strategic consulting on financial and operational issues as well as structuring and funding resources to start-ups and high-growth companies with revenues up to $150 million.

Prior to Gallagher Enterprises, he held senior financial and operations positions at a number of growth oriented entrepreneurial entities including technology firms such as VRex, Viz-rt, Infocus Employee Services, Medsite, Reiss Media Enterprises, Sony Music Entertainment, and the accounting and consulting firm of Arthur Anderson.

Bluefly’s CEO Joseph C. Park commented on the hiring of James Gallagher, “We believe that adding James to our executive team will enable us to better capitalize on strategic and growth opportunities at this exciting time in our company’s evolution.”

For additional information about Bluefly, visit www.bluefly.com

Let us hear your thoughts below:

Pazoo.com, Inc. (PZOO) to Get Comprehensive Facelift with iBuild Media Partnership

Thursday, November 29th, 2012

Online health and wellness social community Pazoo has signed a Web development deal with iBuild Media LLC to boost Pazoo’s online capabilities, presence, feel, and user interactivity.

Pazoo’s goal is to provide its users with information, services, and products designed to improve overall health and wellness. Pazoo anticipates that the agreement will drive a dramatic increase in site traffic, which the company hopes will result in advertising revenue, increased sales, and an increase in awareness for its panel of online experts.

iBuild’s part in this goal is to enhance Pazoo.com through site redesign, site optimization, and content optimization. The current Pazoo.com Web site will be replaced with a site that features total health and wellness feel for people and their pets, and will feature a live chat room that directs the site primarily into a health and wellness social community and platform.

In addition, the e-commerce portion of Pazoo.com will be revamped and have new placement on the Pazoo.com Web site.

“We have a strong corporate business model and I am excited about the fact that we have moved forward with the contract with iBuild Media,” David M. Cunic, CEO of Pazoo stated in the press release. “Pazoo and iBuild Media will put together an online presence that will greatly enhance the end users’ interactivity and knowledge about health and wellness. We are very happy that this online pillar of our business model is coming along so quickly.”

For more information visit www.pazoo.com

Let us hear your thoughts below:

Santa Fe Gold Corp. (SFEG) Hits Bonanza Grade Mineralization While Working Summit Mine, Strong Indicator for Extension Northwest

Thursday, November 29th, 2012

Santa Fe Gold, the ambitious and relatively young mineral developer focused primarily on their flagship Summit silver-gold project (including the underground mine and surrounding 117 patented acres, and 740 unpatented acres) and the associated Banner milling facility in Lordsburg, was overjoyed to report bonanza-grade gold and silver values occurring over mineable widths at Summit today.

We are talking grades of 7.73 opt Au and 269.75 opt Ag, the best results thus far to be pulled at the project. It’s a clear indication that the northern edge of the currently defined resource (especially in light of ongoing explorative work) where the assay material was pulled shows abundant potential for expansion. SFEG is looking at being able to expand northwest along-strike now through high-grade gold and silver, having kicked up this superb news while pursuing the 5600 level of the N-1 ore block.

VP of Operations for SFEG, John White, noted how these findings roundly confirm the company’s model for the N-1 mineralization and have created a great deal of exuberance at SFEG, instilling confidence in the procedural northwesterly movement to the point where the men are actually hungry to get at the metal. The epithermal vein system pattern for Summit is well known to all and here we have solid indicators that digging out more of the NW area will lead to additional high-grade mineralization outside currently identified resources. This could be huge for SFEG and the realization that such additional production potential is within reach has had an electrifying effect on people.

Hitting this kind of potential while working your way through the material is a real boon for SFEG, and though the current assay bonanza returns are likely more highly localized, it is precisely this sort of localized mineralization that is a classic hallmark of epithermal vein systems in this geology. The assays results were encountered near a surface drill hole intersection that returned an 11.4 foot true width at 0.214 opt Au and 16.42 opt Ag, with face channel samples from a three consecutive round interval showing an average of 2.14 opt Au and 82.68 opt Ag over 12.7 feet. An additional 6-foot interval from the same zone yielded the brilliant 7.73 opt Au and 269.75 opt Ag figures.

SFEG will also continue drift development below the 5300 level as they edge towards the high grade stuff down on the 5080 level, a progress target which the company anticipates hitting by the middle of next year. There is plenty of mining to be done within the broad, structurally controlled zone of epithermal mineralization bearing volcanic rock (hydrothermally altered) at Summit and the company has five years of ore reserve just in the main footwall zone (some 618k tons at 0.143 opt Au and 10.78 opt Ag).

Production, discoveries that align with a clear geology model for the mineralization, and growing reserves; it’s a recipe for success and SFEG has their sights set on the big time, with everyone across the company’s asset portfolio driving hard to make Santa Fe the next major player in precious metals development.

For more information on Santa Fe Gold, visit www.SantaFeGoldCorp.com

Let us hear your thoughts below:

The Guitammer Company Inc. (GTMM) Reports Open Market Insider Purchases

Wednesday, November 28th, 2012

The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker® audio transducers, announced today that CEO Mark A. Luden, Chief Financial Officer Rich E. Conn, and Director Walter J. Doyle acquired a collective 156,000 common shares of Guitammer in open market purchases this month. Luden, Conn, and Doyle purchased shares at prices ranging up to $0.35 per share.

“Pursuant to Guitammer’s ‘insider trading policy,’ this represented the first opportunity for Walter, Rich and I to complete open market share purchases since the company began trading on the OTCBB,” stated Mark Luden. “Our collective and growing optimism in Guitammer is based on the financial results the Company has posted year-to-date, noteworthy recent progress across our ButtKicker-branded business as reflected in the increasing global awareness of and demand for our products, and a belief that Guitammer’s patent-protected ButtKicker LIVE!® broadcast technology is moving ever closer to becoming a commercial, recurring revenue-generating reality.”

Today’s news comes on the heels of a press release announcing a 210% increase in third quarter revenue versus the same period a year earlier, in addition to a 189% year-over-year increase in gross profit. Growing popularity of the ButtKicker brand, liquidity capable of supporting continued growth, and the continued development of the company’s patented ButtKicker Live! technology has Guitammer well positioned to further increase shareholder value.

For further information about The Guitammer Company, visit www.guitammer.com, www.thebuttkicker.com, or www.shakemycouch.com

Let us hear your thoughts below:

Cardium Therapeutics, Inc. (CXM) Moving Rapidly with Excellagen

Wednesday, November 28th, 2012

Excellagen, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel designed to facilitate wound care management for diabetic ulcers and many other types of wounds, has been the center of much of Cardium’s recent activity. The product was selected by Podiatry Today, an award-winning monthly publication on foot care, as one of the top 10 podiatry innovations in 2012, and is considered a very promising tool for accelerating the wound healing process. Cardium recently announced the formation of a Medical Advisory Board for Excellagen, made up of leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care. The company also announced the publication of an Excellagen “Profiles in Excellence 2012” article in Podiatry Management and two presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference in Phoenix, Arizona.

Excellagen has been the subject of positive findings by physicians actively using Excellagen, with a number of physicians observing a rapid onset of the growth of granulation tissue, an important part of the wound healing process. In certain cases, rapid granulation tissue growth and wound closure have been reported using Excellagen’s wound care management therapy following unsuccessful treatment with other advanced wound care approaches. In addition, remarkable biological healing responses have been observed following cancer-related Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds.

Having received FDA clearance for Excellagen, Cardium has established cGMP out-sourced manufacturing and supply with UK-based Angel Biotechnology. The company has also developed cold chain logistics and distribution with Smith Medial Partners, and initiated a pathway toward securing private payer and government product reimbursement, including Centers for Medicare & Medicaid Services (CMS), and has assembled an internal strategic and tactical sales and marketing team. The company is currently engaged in physician relationship building with key opinion leaders, product sampling, practice integration, and building a portfolio of physician case studies.

Excellagen has been engineered to serve as a delivery platform enabling multiple device and therapeutic product extensions. The company is currently in discussions with strategic partners to establish representation, marketing and sales, or co-promotional arrangements into various U.S. vertical wound healing market channels.

For additional information, visit www.CardiumTHX.com

Let us hear your thoughts below:

MRI Interventions, Inc. (MRIC) Awarded Frost & Sullivan 2012 Global Company of the Year Award

Wednesday, November 28th, 2012

Commercial stage medical device company MRI Interventions was recognized for its innovative platforms and technologies by receiving the 2012 Global Company of the Year Award in Image-Guided Neural Interventions by Frost & Sullivan, a global business research and consulting firm.

The firm Frost & Sullivan presented the award based on established criteria that included degree of innovation with products and technologies, growth strategy excellence, growth implementation excellence, and leadership in customer value. The firm highlighted MRI Interventions’ Clearpoint® system, which provides an integrated platform for performing a range of minimally-invasive neurological procedures under direct, real-time magnetic resonance imaging (MRI) guidance. The ClearPoint system allows a surgeon to aim the targeting device at a neurological target, and watch in real-time as the surgical instrument is advanced to the target.

“MRI Interventions’ ClearPoint system enables neurological interventions which offer distinct advantages over conventional and robotic procedures,” Frost & Sullivan healthcare industry analyst Beulah Devadason stated in the press release. “The many advantages of this system include reduced patient trauma, and reduction in the overall cost and time required for procedures, which further improves profitability for hospitals.”

To date, ClearPoint systems are being utilized at 16 hospitals in the United States and two hospitals in Europe.

For more information visit www.MRIinterventions.com

Let us hear your thoughts below:

American Apparel, Inc. (APP) Video Chart for Wednesday, November 28, 2012

Wednesday, November 28th, 2012

With a solid day on Tuesday, APP is making a move off a bottom support. The chart is worthy of a look as upward pressure may lead to a test of the first resistance at $1.10.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

Let us hear your thoughts below:

TNI BioTech, Inc. (TNIB) and Immunotherapy

Wednesday, November 28th, 2012

Just as stem cell technology holds out the current best hope for the regeneration of healthy cells, immunotherapy is becoming the latest best hope for efficiently dealing with diseased cells. Although immunotherapy in its broadest form can be said to date back to the pioneering work of 18th century English physician Edward Jenner, who greatly advanced the ancient but dangerous practice of inoculation, the modern practice of manipulating the body’s own immune system to treat disease is often marked by American surgeon William Coley who developed a rudimentary cancer treatment based on provoking an immune response to bacteria around 1891.

Today, although it is still a developing science, immunotherapy has become an important tool for treating various types of cancer, as well as other diseases. It can be used to provide a general boost to the body’s immune system, or can be used to focus the immune response against specific types of cancer cells. In addition, immunotherapy can be used to suppress certain immune system reactions, which is important for preventing rejection of organ transplants or for treating various auto-immune diseases.

TNI BioTech is a Maryland based biotechnology company that uses their own patented immunotherapy technology to mobilize the body’s immune system and combat fatal diseases, including cancer and infectious diseases such as HIV/AIDS. The company’s most advanced clinical program works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. The lymphocytes are then put back into the patient to destroy tumor cells.

The company is currently working with three primary products:

• IRT-101, an active immunotherapy that works by activating a patient’s immune system against infectious diseases and tumor cells
• IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient’s own immune cells
• IRT-103, an active immunotherapy that works by activating a patient’s immune system against HIV/AIDS and tumor cells

For additional information, visit www.TNIBiotech.com

Let us hear your thoughts below:

San Fran’s BART Places Order for 270 AXION International (AXIH) Switch Ties

Wednesday, November 28th, 2012

AXION International Holdings, a green technologies company, today said it has received its third purchase order for an additional 270 ECOTRAX™ switch ties from San Francisco Bay Area Rapid Transit (BART).

BART will install the switch ties along its 104 miles of tracks that connect San Francisco with the suburbs. The heavy-rail public transit and subway system is the 5th busiest rapid transit system in the U.S.

ECOTRAX ties are made from AXION’s patented 100 percent recycled plastic formulation. Because they are inert, the ties are not subject to rotting or absorption of moisture or insect infestation.

“To put this order into perspective,” AXION Material Supply Director Ed Campbell stated in the press release, “we recycled approximately 738,000 high density polyethylene plastic bottles to make these railroad ties.”

AXION noted its penetration in the transit line market in addition to its current customer base in major passenger and freight railways, and said that it has received purchase orders from two more public transit lines, which will conduct trials of ECOTRAX on their systems.

For more information, visit www.AXIH.com

Let us hear your thoughts below:

Vermillion, Inc. (VRML) Appoints Bruce Huebner as Interim CEO

Wednesday, November 28th, 2012

Vermillion, a molecular diagnostics company, announced that director Bruce A. Huebner has been appointed as interim CEO. He is following Gail S. Page, the company’s most recent CEO, who will assist in the transition and serve as a strategic advisor. Mr. Huebner will continue to serve on the board of directors as he assumes his new role.

Mr. Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen, and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace. Huebner was also president and COO of Nanogen, a publicly held nanotechnology and microarray company.

Prior to Nanogen, Mr. Huebner was executive vice president and COO of Gen-Probe, a global leader in the development of nucleic acid tests. In less than 10 years, he grew Gen-Probe’s annual revenues from $42 million to a run-rate of more than $150 million. Huebner is currently a managing director of LynxCom Partners, a healthcare consulting firm with a focus on cancer diagnostics and personalized medicine.

“With more than 37 years of diagnostic industry experience and leadership, as well as serving on a special Vermillion board committee that evaluates marketing strategies for OVA1, Bruce will provide seasoned leadership as our interim CEO,” said James S. Burns, the company’s chairman of the board. “He will actively manage the business and ensure continuity of operations, as our succession committee searches for a new CEO who will take the company to its next level of growth and development.

Burns continued, “I would also like to thank Gail for the leadership and dedication that she has provided in bringing OVA1 to market and a pipeline of products to improve women’s health. We look forward to consulting with Gail in the coming months as we continue to build advocacy for our ovarian cancer franchise among gynecologists and women’s health groups.”

For more information, visit www.vermillion.com

Let us hear your thoughts below:

EntreMed, Inc. (ENMD) Announces Publication of Results of Breast Cancer Preclinical Study

Tuesday, November 27th, 2012

EntreMed, a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. The article is titled “Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models.”

The reports state findings that ENMD-2076 was able to provide anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification. Candidate predictive biomarkers were also identified which may be useful in selecting patients that are particularly sensitive to this compound, ENMD-2076, in the future.

Dr. Jennifer R. Diamond of the University of Colorado School of Medicine, who led the study, commented, “Triple-negative breast cancer is an aggressive breast cancer subtype which carries a high risk of developing metastasis. A major barrier to the successful treatment of metastatic TNBC is the lack of effective targeted anti-cancer agents. Through this study, we show that ENMD-2076 has activity against preclinical models of breast cancer with more robust activity against TNBC. The study also supports further clinical investigation of ENMD-2076 in patients with metastatic TNBC with an emphasis on the continued development of p53-based predictive biomarkers.”

The study was comprised of a diverse panel of twenty-nine breast cancer cell lines representative of the clinically defined breast cancer subtypes which were exposed to ENMD-2076. During the study, the effects on proliferation, apoptosis, and cell cycle distribution were evaluated. The study provided information that is the basis for a predictive biomarker strategy to explore in future clinical trials with ENMD-2076. In this study, ENMD-2076 demonstrated stronger activity against cell lines of the TNBC subtype compared to the luminal and HER2-amplified subtypes. This in vitro activity was confirmed in vivo, in MDA-MB-468 and MDA-MB-231 TNBC xenografts. Baseline gene expression profiling and pathway analysis of the panel revealed that p53 and G1/S cell cycle pathways were unregulated in the more sensitive cell lines. Within the TNBC subset, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and pro-apoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression.

Ken Ren, Ph.D., EntreMed’s Chief Executive Officer further commented, “One of the major challenges for the development of a target therapy for cancer is the identification of a responsive subtype with a predictive biomarker. In our previous Phase 1 study, we observed a patient with TNBC who had failed multiple chemotherapy regimens then had clinically significant stabilization of disease for 41 weeks after ENMD-2076 treatment. The benchmark of median duration after first line therapy in such patients with metastasis is just 12 weeks. This pre-clinical study illustrated scientific insight into the selective sensitivity of TNBC to ENMD-2076 with direct correlation to p53 mutation and over expression. It provides strong support for the rational of our ongoing Phase 2 TNBC trial. Upon further confirmation clinically, it may also provide guidance on future trials for patient selection, and may increase the probability of success. We are continuing to enroll patients in the ongoing Phase 2 trial and anticipate the initiation of a second site for this trial soon. We remain on track with our clinical development activities and expect our progress to accelerate in the coming months and year.”

EntreMed is a clinical-stage pharmaceutical company employing a global drug development strategy primarily in the United States and China. One of the company’s primary compounds, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

For more information, visit www.entremed.com

Let us hear your thoughts below:

Prana Biotechnology Ltd. (PRAN) Completes Patient Enrollment in Alzheimer Trial

Tuesday, November 27th, 2012

Australia-based Prana Biotechnology is focused on commercializing research into age-related neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. The company’s research centers on the interactions between certain metals in the human body and proteins.

The company announced today that it has completed enrollment in the IMAGINE trial, a 12-month Phase II trial testing PBT2, the company’s drug in development for Alzheimer’s disease. This disease affects more than 26 million people around the globe. All currently available treatments only offer some degree of symptomatic relief, but none change the course of the disease. PBT2 has the potential to actually treat the disease.

The Phase II study is a double-blind placebo controlled trial and has enrolled 41 patients with mild Alzheimer’s disease in Melbourne, Australia. Trial participants are undergoing brain scans to measure PBT2′s effect on amyloid deposits in the brain and effects on increasing brain activity. Neuropsychological Test Battery (NTB) is being used to measure the cognition effects.

Scientific data supporting the belief that PBT2 can bring clinical benefit to patients is extensive. An earlier 12-week Alzheimer’s disease trial showed the drug significantly reduced the level of Abeta protein in the spinal fluid of treated patients as well as improving their cognitive function. PBT2 is believed to restore neuronal health by binding and redistributing brains metals (copper, zinc) that have become imbalanced.

For additional information about Prana Biotechnology and its PBT2 Alzheimer’s drug, visit www.pranabio.com

Let us hear your thoughts below:

Shoreline Energy Corp. (SEQ.TO) to Provide Investor Update via Conference Call Tomorrow

Tuesday, November 27th, 2012

Shoreline Energy Corp. is planning to hold a conference call tomorrow, November 28, 2012, to discuss its recent business developments, including the impact and outlook relating to its acquisition of the Wattenberg Colorado Project located in the Denver-Julesberg Basin.

The Wattenberg Colorado Project represents Shoreline’s initial entry into the United States. This project is currently an area of a large scale, low risk horizontal development well program, using multi-stage frac technology. Acquisition of the project is expected to generate $4.6m of cash flows the first year, providing an initial rate of return of more than 30%.

The CEO of Shoreline will be hosting the conference call. Those who wish to participate should dial in at 11:30am ET using 1-877-317-6776 with the conference ID 10021652. International callers should use the same conference code, but dial 1-412-317-0088 instead. The conference will also be available via webcast at the following link: http://webcast.mzvaluemonitor.com/Home/Login/648.

A slide presentation for the call will be available on the company’s website at the start of the call. After the prepared presentations, investors will be given the opportunity to ask questions.

Investors unable to attend at the scheduled time can access a recording of the call. To listen, call 1-877-344-7529 within the United States or 1-412-317-0088 when calling internationally. The replay pin number required to access the recording is 10021652.

For more information, visit www.shorelineenergy.ca

Let us hear your thoughts below: